Rituximab Biosimilar(Shanghai Institute Of Biological Products)

利妥昔单抗生物类似药（上海生物制品研究所）

Report date: 2026/05/20 20:02:01

Base Information

Drug NameRituximab Biosimilar(Shanghai Institute Of Biological Products)
Drug Alias Name生利健SIBP-02
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibodyBiologics > Biosimilar
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsComplement dependent cytotoxicity (CDC) effectsCD20-directed cytolytic effects +[4] 
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLeukemia, Lymphocytic, Chronic, B-Cell
Approved Indications in ChinaLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLeukemia, Lymphocytic, Chronic, B-Cell
Original Approved Country/TerritoryMainland China
Original Approved Date2024/03/19
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShanghai Institute of Biological Products Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteShanghai Institute of Biological Products Co Ltd
Inactive CompaniesN/A
Active IndicationsLymphoma, FollicularLymphoma, Large B-Cell, DiffuseLeukemia, Lymphocytic, Chronic, B-Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A